ABOUT US
MC2 Therapeutics is a commercial stage biopharmaceutical company committed to redefine the treatment experience for people with autoimmune and chronic inflammatory skin and eye conditions. Read more about MC2 Therapeutics.
Platform
Our PAD Technology™ formulation and drug delivery system offer several unique advantages in the development of potent innovative new topical therapies for auto-immune and inflammatory conditions, including stability, tolerability, delivery to target tissue and convenience of use in daily routines. Read more about our platform.
Pipeline
MC2 therapeutics is uncovering new topical therapies within the field of autoimmune and inflammatory conditions. We are proud to take leadership in setting a new standard powered by our PAD Technology™, our research into the root causes of poorly understood autoimmune and chronic inflammatory conditions and our ability to effectively execute on development of best in class or first in class innovative topical therapies. Read more about our pipeline.
